Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15157682 | 1.00 | GPR3 (0.35) | GPR3 | |
| SCHEMBL15157684 | 1.00 | GPR3 (0.35) | GPR3 | |
| SCHEMBL29060308 | 1.00 | GPR3 (0.35) | GPR3 | |
| SCHEMBL219698 | 0.80 | — | — | |
| SCHEMBL219699 | 0.80 | — | — | |
| SCHEMBL22230365 | 0.79 | NR4A1 (0.47) | GPR3 | |
| SCHEMBL29504028 | 0.79 | NR4A1 (0.47) | GPR3 | |
| SCHEMBL22230368 | 0.79 | NR4A1 (0.47) | GPR3 | |
| SCHEMBL12315085 | 0.79 | NR4A1 (0.47) | GPR3 | |
| SCHEMBL29662301 | 0.79 | NR4A1 (0.47) | GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-9884860-B2 | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2018-02-06 | — | — | US | disclosed |
| US-9884860-B2 | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2018-02-06 | — | — | US | disclosed |
| EP-2809669-B1 | FUSED PYRROLEDICARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-02-01 | — | — | EP | disclosed |
| US-20160159793-A1 | Fused Pyrroledicarboxamides and Their Use as Pharmaceuticals | SANOFI (FR) | 2016-06-09 | — | — | US | disclosed |
| US-20160159793-A1 | Fused Pyrroledicarboxamides and Their Use as Pharmaceuticals | SANOFI (FR) | 2016-06-09 | — | — | US | disclosed |
| US-9284333-B2 | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2016-03-15 | — | — | US | disclosed |
| WO-2013113860-A1 | FUSED PYRROLEDICARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | GPR3 4453/4885 |
| US-20160159793-A1 | Fused Pyrroledicarboxamides and Their Use as Pharmaceuticals | KCNA1, KCNE1, KCNH1 | GPR3 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.